Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1–3 at initiat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gansevoort, Ron T., Arici, Mustafa, Benzing, Thomas, Birn, Henrik, Capasso, Giovambattista, Covic, Adrian, Devuyst, Olivier, Drechsler, Christiane, Eckardt, Kai-Uwe, Emma, Francesco, Knebelmann, Bertrand, Le Meur, Yannick, Massy, Ziad A., Ong, Albert C.M., Ortiz, Alberto, Schaefer, Franz, Torra, Roser, Vanholder, Raymond, Więcek, Andrzej, Zoccali, Carmine, Van Biesen, Wim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Cutting-Edge Renal Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762400/
https://www.ncbi.nlm.nih.gov/pubmed/26908832
http://dx.doi.org/10.1093/ndt/gfv456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762400/
https://www.ncbi.nlm.nih.gov/pubmed/26908832
http://dx.doi.org/10.1093/ndt/gfv456

Ejemplares similares